Launched in 2010 with a $25 million Series A financing led by Third Rock Ventures, Foundation Medicine released its first commercial assay called FoundationOne in 2012. The company develops, manufactures, and sells genomic profiling assays based on next-generation sequencing technology for solid tumours, hematologic malignancies, and sarcomas. In December 2017, the company’s assay FoundationOne...
At the Digital Medicine Connect in Boston this week, presenters wrestled with the question of what it would take to spur wider adoption of digital therapies. With Omada CEO Sean Duffy on the panel, it’s not surprising that one common answer — more and better efficacy data — came up. But also, speakers including Vidya Raman-Tangella, head of United Healthcare’s Innovation Center of Excellence and...
